Pipeline

Our research pipeline is designed to develop treatments for genetically defined subpopulations of patients suffering from dry AMD and linked diseases. This could provide patients with access to targeted first-in-class medicines for patients with limited therapeutic options.

Ocular Disease Platform

Research
Preclinical
Clinical

Age-Related Macular Degeneration

CLARITY Natural History Study and Registry

Status: Clinical


Precision Medicine Pipeline

Research
Preclinical
Clinical

Age-Related Macular Degeneration

GEM103

Target: Complement Factor H

Modality: Recombinant Protein

Status: Clinical


AAV-CFH

Target: Complement Factor H

Modality: Gene Therapy

Status: Preclinical


GEM104

Target: Complement Factor I

Modality: Recombinant Protein

Status: Preclinical


AAV-CFI

Target: Complement Factor I

Modality: Gene Therapy

Status: Preclinical


Ocular Disease

mAb

Target: HTRA1

Modality: Monoclonal Antibody

Status: Research


AAV-Ab

Target: HTRA1

Modality: Gene Therapy

Status: Research


Systemic Renal

GEM307

Target: Complement Factor H

Modality: Monoclonal Antibody

Status: Preclinical